ANAB250117C15000
- 0.25
- -1.00-80.00%
AnaptysBio Newsroom
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41
Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating
AnaptysBio Analyst Ratings
AnaptysBio Is Maintained at Overweight by Wells Fargo
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $32
AnaptysBio (ANAB) Receives a Buy From TD Cowen
AnaptysBio Analyst Ratings
Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy
HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target
Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating
BTIG Maintains AnaptysBio(ANAB.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)